Yahoo Finance

Mitsubishi Tanabe Pharma America to Share Latest Data on Investigational ND0612 at the 2025 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD)

JERSEY CITY, N.J., March 31, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that three poster presentations on investigational ND0612 in Parkinson's disease (PD) ...
Yahoo Finance

Mitsubishi Tanabe Pharma America Announces U.S. FDA Acceptance of New Drug Application Resubmission for Investigational ND0612 for the Treatment of Motor Fluctuations in ...

JERSEY CITY, N.J., May 28, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application ...
Medical Xpress

Subcutaneous infusion of levodopa-carbidopa beneficial for Parkinson's disease

Subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) increases on time without troublesome dyskinesia among patients with Parkinson disease, according to a study published online March 15 ...
PR Newswire

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

REHOVOT, Israel, March 18, 2024 /PRNewswire/ -- NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced the publication of results in The Lancet ...
Medindia

NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a ...
WTNH

Mitsubishi Tanabe Pharma America Announces Publication of Positive Results from Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson's Disease ...

Pivotal Phase 3 data, published in The Lancet Neurology, showed favorable efficacy of ND0612 compared to oral immediate-release levodopa/carbidopa JERSEY CITY, N.J., March 18, 2024 /PRNewswire/ -- ...
Healio

Continuous subcutaneous infusion linked to more ‘on’ time in Parkinson’s

Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...
Finanznachrichten

NeuroDerm, Ltd.: NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

About ND0612 ND0612 is an investigational drug-device combination therapy - a 24-hours/day, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor ...
FiercePharma

NeuroDerm Announces Enrollment in a Second Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a ...
PR Newswire

NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

ND0612, a continuous 24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the primary endpoint ("ON" time without ...